APA (7th ed.) Citation

C, G., A, F., O, W., Y, M., B, K., N, D., . . . Y, O. (2025). CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study. British journal of haematology, 206(2), 551. https://doi.org/10.1111/bjh.19967

Chicago Style (17th ed.) Citation

C, Ganzel, et al. "CPX-351 +/- Gemtuzumab Ozogamicin as Induction Therapy for Adult Patients with Newly Diagnosed, Favourable-intermediate Risk, FLT3-ITD Negative, AML: A Pilot Study." British Journal of Haematology 206, no. 2 (2025): 551. https://doi.org/10.1111/bjh.19967.

MLA (9th ed.) Citation

C, Ganzel, et al. "CPX-351 +/- Gemtuzumab Ozogamicin as Induction Therapy for Adult Patients with Newly Diagnosed, Favourable-intermediate Risk, FLT3-ITD Negative, AML: A Pilot Study." British Journal of Haematology, vol. 206, no. 2, 2025, p. 551, https://doi.org/10.1111/bjh.19967.